The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.
|Number of pages||6|
|Journal||Journal of Hypertension|
|Publication status||Published - 2004|
Dawson, A., Rana, B. S., Pringle, S. D., Donnelly, L. A., Morris, A. D., & Struthers, A. D. (2004). How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? Journal of Hypertension, 22(7), 1403-8. https://doi.org/10.1097/01.hjh.0000125408.50839.b8